HPP737 in Moderate to Severe Plaque Psoriasis

Phase 3, randomised, double-blind trial of HPP737 in plaque psoriasis (2 arms), sponsored by Newsoara Biopharma. Primary endpoints: Proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index at 16 weeks and Proportion of subjects achieving Static Physician's Global Assessment rating of clear or almost clear at 16 weeks. Started Apr 2025; status: completed.